or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    NVS D 0.88 0.53

    Represented by ETF Holdings

    Keywords: Active Pharmaceutical Ingredients Animal Health Antibiotics Biotechnology Blood Test Contact Lens Contact Lenses Diagnostic Products Disposable Product Disposable Products Drugs Eye Eye Care Eye Care Products Eyewear Healthcare Products Infectious Diseases Intraocular Lens Lens Care Products Lenses
    Industries: Drug Manufacturers - Major

    Recent News for PowerShares DWA Developed Market Technical Leaders Portfolio & its Holdings

    Date Stock Title
    Nov 1 NVS Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus
    Nov 1 NVS Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
    Nov 1 NVS Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
    Oct 31 NVS REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
    Oct 30 NVS Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
    Oct 30 NVS Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
    Oct 30 NVS BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised
    Oct 30 NVS ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
    Oct 30 NVS Novartis’ Scemblix gains FDA approval for leukaemia
    Oct 30 NVS Novartis: It's Not Too Late To Buy This Dividend Stock Now
    Oct 30 NVS Novartis Reports Strong Q3 Growth and Raises Guidance
    Oct 30 NVS Novartis AG (NVS) Q3 2024 Earnings Call Highlights: Record Cash Flow and Robust Sales Growth
    Oct 29 NVS Novartis: Strong Financials, But Market Skepticism Persists Amid Pipeline Concerns
    Oct 29 NVS Novartis wins first-line chronic myeloid leukemia indication for Scemblix
    Oct 29 NVS Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
    Oct 29 NVS Novartis Stock Dives on $800 Million Write-Down
    Oct 29 NVS Novartis Ag (NVS) Q3 2024 Earnings Call Transcript
    Oct 29 NVS Top Midday Stories: McDonald's Beats Estimates on Q3 EPS, Revenue, Misses on Same-Store Sales; Ford Lowers EBIT Guidance
    Oct 29 NVS Novartis AG (NVS) Q3 2024 Earnings Call Transcript
    Oct 29 NVS Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler
    The PowerShares DWA Developed Markets Momentum Portfolio (Fund) is based on the Dorsey Wright® Developed Markets Technical Leaders Index ND (Index). The Fund will normally invest at least 80% of its total assets in securities of developed economies within Dorsey, Wright & Associates, LLC's classification definition, excluding US companies listed on a US stock exchange. This Index includes approximately 100 companies that possess powerful relative strength characteristics and are domiciled in developed markets including, but not limited to Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Hong Kong, Ireland, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Singapore, Spain, Sweden, Switzerland and the United Kingdom. The Index excludes US companies listed on a US stock exchange. The Index is computed using the net return, which withholds applicable taxes for non-resident investors. The Fund and the Index are rebalanced and reconstituted quarterly. Effective on or about Oct. 4, 2013, the name of the Fund changed from PowerShares DWA Developed Markets Technical Leaders Portfolio to PowerShares DWA Developed Markets Momentum Portfolio
    Exchange Traded Fund ETF Exchange Traded Funds Invesco Powershares Relative Strength Leaders Index Nasdaq 100 Settlement Index
    Back to the Main PIZ Page...